GlassScriptPhysician profile
Michael Kirkwood
NPI 1336144112
$802.06
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $79.62 · 2021: $52.31.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $418.16 | 2019-2020 | |
| Avanos Medical | $117.18 | 2019 | |
| Boston Scientific Corporation | $93.10 | 2019 | |
| Amag Pharmaceuticals, INC. | $40.59 | 2019 | |
| Meditrina | $28.19 | 2021 | |
| Ethicon US, LLC | $24.12 | 2021 | |
| Duchesnay USA Incorporated | $16.61 | 2019 | |
| Merck Sharp & Dohme LLC | $16.39 | 2020 | |
| Therapeuticsmd, INC. | $13.34 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.92 | 2020 | |
| Avion Pharmaceuticals | $10.83 | 2019 | |
| Daiichi Sankyo INC. | $10.63 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kirkwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.